China NT Pharma Group Company Limited (1011.HK)
HKD 0.41
(-7.87%)
HKD 0.41
(-7.87%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -13.01 Million CNY | -132.94% |
| 2022 | 10.39 Million CNY | 332.01% |
| 2021 | -17.77 Million CNY | 61.07% |
| 2020 | -43.73 Million CNY | -581.47% |
| 2019 | -155.97 Million CNY | 104.31% |
| 2018 | -210.91 Million CNY | -167.69% |
| 2017 | 303.56 Million CNY | 46.12% |
| 2016 | 86.28 Million CNY | 24.6% |
| 2015 | 143.25 Million CNY | 90.64% |
| 2014 | 118.53 Million CNY | 168.48% |
| 2013 | -555.43 Million CNY | 68.76% |
| 2012 | -1.09 Billion CNY | -207.67% |
| 2011 | 389.79 Million CNY | 42.8% |
| 2010 | 272.96 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -1.38 Million CNY | 0.0% |
| 2023 Q2 | -2.56 Million CNY | 0.0% |
| 2023 FY | - CNY | -132.94% |
| 2022 Q4 | 26.49 Million CNY | 0.0% |
| 2022 Q2 | 9.58 Million CNY | 0.0% |
| 2022 FY | - CNY | 332.01% |
| 2021 FY | - CNY | 61.07% |
| 2021 Q4 | -54.34 Million CNY | 0.0% |
| 2021 Q2 | -2.92 Million CNY | 0.0% |
| 2020 Q2 | -14.47 Million CNY | 0.0% |
| 2020 FY | - CNY | -581.47% |
| 2019 FY | - CNY | 104.31% |
| 2019 Q2 | -13.64 Million CNY | 0.0% |
| 2018 FY | - CNY | -167.69% |
| 2018 Q4 | - CNY | 0.0% |
| 2018 Q2 | 149.67 Million CNY | 0.0% |
| 2017 Q2 | 150.24 Million CNY | 0.0% |
| 2017 Q4 | - CNY | 0.0% |
| 2017 FY | - CNY | 46.12% |
| 2016 Q2 | 67.59 Million CNY | 0.0% |
| 2016 Q4 | - CNY | 0.0% |
| 2016 FY | - CNY | 24.6% |
| 2015 FY | - CNY | 90.64% |
| 2015 Q2 | 68.38 Million CNY | 0.0% |
| 2015 Q4 | 84.21 Million CNY | 0.0% |
| 2014 Q4 | 58.86 Million CNY | 0.0% |
| 2014 FY | - CNY | 168.48% |
| 2014 Q2 | 46.72 Million CNY | 0.0% |
| 2013 Q4 | -65.79 Million CNY | 0.0% |
| 2013 FY | - CNY | 68.76% |
| 2013 Q2 | -83.15 Million CNY | 0.0% |
| 2012 Q2 | - CNY | 0.0% |
| 2012 FY | - CNY | -207.67% |
| 2012 Q4 | - CNY | 0.0% |
| 2011 FY | - CNY | 42.8% |
| 2011 Q4 | - CNY | 0.0% |
| 2011 Q2 | - CNY | 0.0% |
| 2010 FY | - CNY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 150.4 Million HKD | 108.654% |
| Grand Pharmaceutical Group Limited | 2.96 Billion HKD | 100.439% |
| Extrawell Pharmaceutical Holdings Limited | -129.51 Million HKD | 89.951% |
| Wai Yuen Tong Medicine Holdings Limited | 113.79 Million HKD | 111.437% |
| Qianhai Health Holdings Limited | -50.22 Million HKD | 74.089% |
| Lee's Pharmaceutical Holdings Limited | 109.82 Million HKD | 111.851% |
| Essex Bio-Technology Limited | 418.37 Million HKD | 103.111% |
| Tongfang Kontafarma Holdings Limited | 76.63 Million HKD | 116.984% |
| PuraPharm Corporation Limited | -26.16 Million HKD | 50.266% |
| SSY Group Limited | 2.11 Billion HKD | 100.615% |
| JBM (Healthcare) Limited | 204.39 Million HKD | 106.368% |
| Jacobson Pharma Corporation Limited | 429.92 Million HKD | 103.027% |
| China Resources Pharmaceutical Group Limited | 15.43 Billion HKD | 100.084% |